---
title: "《回顧》國指 2025 年上半年五大最強及最弱股份 (表)"
description: "國指 2025 年上半年表現總結：五大最強股份為小米-W(+73.8%)、石藥 (+61.1%)、快手-W(+53.1%)、京東健康 (+53.0%)、網易-S(+52.5%)；五大最弱股份為海爾智家 (-18.4%)、美團-W(-17.4%)、攜程-S(-15.6%)、新東方-S(-13.9%)、申洲國際 (-10.0%)。國指累計升幅為 1,388 點，漲幅 19.0%，收於 8,678 點。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/246635110.md"
published_at: "2025-06-30T09:23:31.000Z"
---

# 《回顧》國指 2025 年上半年五大最強及最弱股份 (表)

> 國指 2025 年上半年表現總結：五大最強股份為小米-W(+73.8%)、石藥 (+61.1%)、快手-W(+53.1%)、京東健康 (+53.0%)、網易-S(+52.5%)；五大最弱股份為海爾智家 (-18.4%)、美團-W(-17.4%)、攜程-S(-15.6%)、新東方-S(-13.9%)、申洲國際 (-10.0%)。國指累計升幅為 1,388 點，漲幅 19.0%，收於 8,678 點。

國指 2025 年上半年五大最強股份：

股份│上半年股價變幅

小米-W(01810.HK)│+73.8%

石藥 (01093.HK)│+61.1%

快手-W(01024.HK)│+53.1%

京東健康 (06618.HK)│+53.0%

網易-S(09999.HK)│+52.5%

國指 2025 年上半年五大最弱股份：

股份│上半年股價變幅

海爾智家 (06690.HK)│-18.4%

美團-W(03690.HK)│-17.4%

攜程-S(09961.HK)│-15.6%

新東方-S(09901.HK)│-13.9%

申洲國際 (02313.HK)│-10.0%

總結國指 2025 上半年累升 1,388 點或 19.0%，收 8,678 點。

### Related Stocks

- [06618.HK - 京東健康](https://longbridge.com/zh-HK/quote/06618.HK.md)
- [01093.HK - 石藥集團](https://longbridge.com/zh-HK/quote/01093.HK.md)
- [09901.HK - 新東方-S](https://longbridge.com/zh-HK/quote/09901.HK.md)
- [02313.HK - 申洲國際](https://longbridge.com/zh-HK/quote/02313.HK.md)
- [01024.HK - 快手-W](https://longbridge.com/zh-HK/quote/01024.HK.md)
- [09999.HK - 網易-S](https://longbridge.com/zh-HK/quote/09999.HK.md)
- [06690.HK - 海爾智家](https://longbridge.com/zh-HK/quote/06690.HK.md)
- [03690.HK - 美團-W](https://longbridge.com/zh-HK/quote/03690.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/zh-HK/news/276056763.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |
| China tightens oversight of online ticket platforms, targets paid priority purchase claims | The Beijing Municipal Administration for Market Regulation has conducted interviews with 12 major online ticket platform | [Link](https://longbridge.com/zh-HK/news/275689507.md) |
| CICC Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF) | CICC has reaffirmed its Buy rating for CSPC Pharmaceutical Group (CHJTF) with a price target of HK$12.00. Additionally,  | [Link](https://longbridge.com/zh-HK/news/274393834.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。
